12/03/2014 - 14:15
An immunomodulator that targets the PD-1 pathway effected sustained remission in 31% of patients who took it for advanced melanoma.
Remission lasted a median of 2 years, with 1- and 2-year overall...
Field of Interest: Oncology
Categories:
News Feed: Internal Medicine News - Oncology